Among the FLT3 inhibitors mentioned, only two agents, midostaurin (RydaptVR) and gilteritinib (XospataVR), obtained FDA clearance for the treatment of FLT3-mutated AML in 2017 and 2018, respectively. Here, FLT3 is linked to acute myeloid leukemia.